Search Results - "Moyo, Tamara"

SynSeg-Net: Synthetic Segmentation Without Target Modality Ground Truth by Huo, Yuankai, Xu, Zhoubing, Moon, Hyeonsoo, Bao, Shunxing, Assad, Albert, Moyo, Tamara K., Savona, Michael R., Abramson, Richard G., Landman, Bennett A.

“…A key limitation of deep convolutional neural network (DCNN)-based image segmentation methods is the lack of generalizability. Manually traced training images…”
Get full text

Re-examining the role of hematopoietic stem cell transplantation in relapsed large B-cell lymphoma in the era of chimeric antigen receptor (CAR) T-cell therapy by Moyo, Tamara K, Vaidya, Rakhee

“…Historically, salvage chemoimmunotherapy with consolidative autologous hematopoietic stem cell transplantation (ASCT) was the only potentially curative…”
Get full text

Revisiting the role of autologous stem cell transplant in relapsed/ refractory aggressive B cell lymphoma by Moyo, Tamara K.

Get full text

Splenomegaly Segmentation on Multi-Modal MRI Using Deep Convolutional Networks by Huo, Yuankai, Xu, Zhoubing, Bao, Shunxing, Bermudez, Camilo, Moon, Hyeonsoo, Parvathaneni, Prasanna, Moyo, Tamara K., Savona, Michael R., Assad, Albert, Abramson, Richard G., Landman, Bennett A.

“…The findings of splenomegaly, abnormal enlargement of the spleen, is a non-invasive clinical biomarker for liver and spleen diseases. Automated segmentation…”
Get full text

A Review of Chimeric Antigen Receptor T-Cell Therapy for Myeloma and Lymphoma by Atrash, Shebli, Moyo, Tamara K

“…Collectively, hematological malignancies account for the fourth most common malignancy. Myeloma and lymphoma are the most common types of hematological…”
Get full text

MicroRNA-31 initiates lung tumorigenesis and promotes mutant KRAS-driven lung cancer by Edmonds, Mick D, Boyd, Kelli L, Moyo, Tamara, Mitra, Ramkrishna, Duszynski, Robert, Arrate, Maria Pia, Chen, Xi, Zhao, Zhongming, Blackwell, Timothy S, Andl, Thomas, Eischen, Christine M

“…MicroRNA (miR) are important regulators of gene expression, and aberrant miR expression has been linked to oncogenesis; however, little is understood about…”
Get full text

Rituximab, lenalidomide, and ibrutinib in relapsed/refractory primary cutaneous diffuse large B‐cell lymphoma, leg type by Moore, Donald C., Soni, Amy C., Hu, Bei, Smith, Elton T., Levine, Jonathan, Moyo, Tamara K., Jacobs, Ryan, Ghosh, Nilanjan, Park, Steven I.

Get full text

Equal access to care and nurse navigation leads to equitable outcomes for minorities with aggressive large B-cell lymphoma by Hu, Bei, Boselli, Danielle, Pye, Lisa M, Chen, Tommy, Bose, Rupali, Symanowski, James T, Blackley, Kris, Moyo, Tamara K, Jacobs, Ryan, Park, Steven I, Soni, Amy, Avalos, Belinda R, Copelan, Edward A, Raghavan, Derek, Ghosh, Nilanjan

“…Aggressive large B-cell lymphomas (LBCLs) are curable, but previous studies have shown inferior outcomes in minorities. Nurse navigation programs can improve…”
Get full text

Bone marrow infiltration by multiple myeloma causes anemia by reversible disruption of erythropoiesis by Bouchnita, Anass, Eymard, Nathalie, Moyo, Tamara K., Koury, Mark J., Volpert, Vitaly

“…Multiple myeloma (MM) infiltrates bone marrow and causes anemia by disrupting erythropoiesis, but the effects of marrow infiltration on anemia are difficult to…”
Get full text

PI3K Inhibition Restores and Amplifies Response to Ruxolitinib in Patients with Myelofibrosis by Moyo, Tamara K, Kishtagari, Ashwin, Villaume, Matthew T, McMahon, Brandon, Mohan, Sanjay R, Stopczynski, Tess, Chen, Sheau-Chiann, Fan, Run, Huo, Yuankai, Moon, Hyeonsoo, Tang, Yucheng, Bejan, Cosmin A, Childress, Merrida, Anderson, Ingrid, Rawling, Kyle, Simons, Rhea M, Moncrief, Ashley, Caza, Rebekah, Dugger, Laura, Collins, Aunshka, Dudley, Channing V, Ferrell, P Brent, Byrne, Michael, Strickland, Stephen A, Ayers, Gregory D, Landman, Bennett A, Mason, Emily F, Mesa, Ruben A, Palmer, Jeanne M, Michaelis, Laura C, Savona, Michael R

“…Treatment options are limited beyond JAK inhibitors for patients with primary myelofibrosis (MF) or secondary MF. Preclinical studies have revealed that PI3Kδ…”
Get full text

Corrigendum to “Acceleration of spleen segmentation with end-to-end deep learning method and automated pipeline” [Comput. Biol. Med. 107 (2019) 109–117] by Moon, Hyeonsoo, Huo, Yuankai, Abramson, Richard G., Peters, Richard Alan, Assad, Albert, Moyo, Tamara K., Savona, Michael R., Landman, Bennett A.

Get full text

Acceleration of spleen segmentation with end-to-end deep learning method and automated pipeline by Moon, Hyeonsoo, Huo, Yuankai, Abramson, Richard G., Peters, Richard Alan, Assad, Albert, Moyo, Tamara K., Savona, Michael R., Landman, Bennett A.

“…Delineation of Computed Tomography (CT) abdominal anatomical structure, specifically spleen segmentation, is useful for not only measuring tissue volume and…”
Get full text

The delta isoform of phosphatidylinositol-3-kinase predominates in chronic myelomonocytic leukemia and can be targeted effectively with umbralisib and ruxolitinib by Villaume, Matthew T., Arrate, M. Pia, Ramsey, Haley E., Sunthankar, Kathryn I., Jenkins, Matthew T., Moyo, Tamara K., Smith, Brianna N., Fischer, Melissa A., Childress, Merrida A., Gorska, Agnieszka E., Ferrell, P. Brent, Savona, Michael R.

“…•PI3k-δ is the most abundant PI3K subunit among monocytic leukemia samples.•CMML patient samples are uniquely sensitive to PI3K-δ inhibition by…”
Get full text

Peri–CAR-T practice patterns and survival predictors for all CAR-T patients and post–CAR-T failure in aggressive B-NHL by Zurko, Joanna, Nizamuddin, Imran, Epperla, Narendranath, David, Kevin, Cohen, Jonathon B., Moyo, Tamara K., Ollila, Thomas, Hess, Brian, Roy, Ishan, Ferdman, Robert, Liu, Jieqi, Chowdhury, Sayan Mullick, Romancik, Jason, Bhansali, Rahul S., Harris, Elyse I., Sorrell, Mckenzie, Masel, Rebecca, Kittai, Adam S., Denlinger, Nathan, Sigmund, Audrey M., Fitzgerald, Lindsey, Galvez, Carlos, Ma, Shuo, Winter, Jane, Pro, Barbara, Gordon, Leo I., Danilov, Alexey, Stephens, Deborah, Shah, Nirav N., Kenkre, Vaishalee, Barta, Stefan K., Torka, Pallawi, Shouse, Geoffrey, Karmali, Reem

“…•Bridging therapy and more lines of pre–CAR-T therapy were associated with inferior PFS and OS after CAR-T for aggressive B-cell lymphoma.•Post–CAR-T failure,…”
Get full text

Therapy for Chronic Myelomonocytic Leukemia in a New Era by Moyo, Tamara K., Savona, Michael R.

“…Chronic myelomonocytic leukemia (CMML) is a myeloid malignancy which shares clinical and morphologic features of myelodysplastic syndromes (MDS) and…”
Get full text

Subsequent malignant neoplasms in patients previously treated with anti-CD19 CAR T-cell therapy by Melody, Megan, Epperla, Narendranath, Shouse, Geoffrey, Romancik, Jason, Allen, Pamela, Moyo, Tamara K., Kenkre, Vaishalee, Ollila, Thomas, Fitzgerald, Lindsey, Hess, Brian, David, Kevin, Herr, Megan M., Odetola, Oluwatobi, Lin, Adam, Moreira, Jonathan, Ma, Shuo, Winter, Jane N., Roy, Ishan, Stephens, Deborah, Danilov, Alexey, Shah, Nirav N., Barta, Stefan K., Cortese, Matthew, Cohen, Jonathon B., Gordon, Leo I., Karmali, Reem

Get full text

Impact of race and social determinants of health on outcomes in patients with aggressive B-cell NHL treated with CAR-T therapy by Karmali, Reem, Machhi, Rushad, Epperla, Narendranath, Shouse, Geoffrey, Romancik, Jason, Moyo, Tamara K., Kenkre, Vaishalee, Ollila, Thomas A., Fitzgerald, Lindsey, Hess, Brian, David, Kevin, Roy, Ishan, Zurko, Joanna, Chowdhury, Sayan Mullick, Annunzio, Kaitlin, Ferdman, Robert, Bhansali, Rahul S., Harris, Elyse I., Liu, Jieqi, Nizamuddin, Imran, Ma, Shuo, Moreira, Jonathan, Winter, Jane, Pro, Barbara, Stephens, Deborah M., Danilov, Alexey, Shah, Nirav N., Cohen, Jonathon B., Barta, Stefan K., Torka, Pallawi, Gordon, Leo I.

“…•Racial disparities exist in patients who received CAR-T therapy for aggressive B-NHL.•Payor status affects survival, with improved survival noted in Medicare…”
Get full text

Genotypic and clinical heterogeneity within NCCN favorable-risk acute myeloid leukemia by Strickland, Stephen A., Shaver, Aaron C., Byrne, Michael, Daber, Robert D., Ferrell, P. Brent, Head, David R., Mohan, Sanjay R., Mosse, Claudio A., Moyo, Tamara K., Stricker, Thomas P., Vnencak-Jones, Cindy, Savona, Michael R., Seegmiller, Adam C.

“…•This study identified differences in the characteristics of favorable-risk AML.•AML with normal karyotype and NPM1 mutations is distinct in age and…”
Get full text

Molecular Testing in Patients with Suspected Myelodysplastic Syndromes by Moyo, Tamara K., Savona, Michael R.

“…Myelodysplastic syndromes (MDS) comprise a heterogeneous group of clonal hematologic malignancies characterized by a hypercellular bone marrow and morphologic…”
Get full text

Late Psychiatric and Neurocognitive Effects of Chimeric Antigen Receptor T Cell Therapy Warrant Further Investigation by Moyo, Tamara K.

Get full text